Get the Stockscreener App
3.58
9.82%
-0.39
After Hours:
3.60
0.02
+0.56%
Ataibeckley Inc stock is traded at $3.58, with a volume of 3.99M.
It is down -9.82% in the last 24 hours and down -4.79% over the past month.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
See More
Previous Close:
$3.97
Open:
$3.93
24h Volume:
3.99M
Relative Volume:
1.07
Market Cap:
$1.30B
Revenue:
$2.59M
Net Income/Loss:
$-137.89M
P/E Ratio:
-4.4198
EPS:
-0.81
Net Cash Flow:
$-69.76M
1W Performance:
+4.99%
1M Performance:
-4.79%
6M Performance:
-13.32%
1Y Performance:
+40.39%
1-Day Range:
$3.58
$3.935
1-Week Range:
$3.44
$4.01
52-Week Range:
$1.15
$6.75
Ataibeckley Inc Stock (ATAI) Company Profile
Name
Ataibeckley Inc
Sector
Industry
Phone
49 89 2153 9035
Address
PROF. J.H. BAVINCKLAAN 7, AMSTELVEEN
Compare ATAI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATAI
Ataibeckley Inc
|
3.58 | 1.44B | 2.59M | -137.89M | -69.76M | -0.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-20-26 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Needham | Buy |
| Jul-29-25 | Initiated | Oppenheimer | Outperform |
| Nov-18-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-03-24 | Upgrade | Maxim Group | Hold → Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
| Nov-11-21 | Initiated | ROTH Capital | Buy |
| Oct-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-01-21 | Initiated | Jefferies | Buy |
| Jul-13-21 | Initiated | Berenberg | Buy |
| Jul-13-21 | Initiated | Canaccord Genuity | Buy |
| Jul-13-21 | Initiated | Cantor Fitzgerald | Buy |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-13-21 | Initiated | Credit Suisse | Outperform |
| Jul-13-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-08-21 | Initiated | Aegis Capital | Buy |
View All
Ataibeckley Inc Stock (ATAI) Latest News
5 Psychedelic Stocks to Buy Now - The Motley Fool
Guggenheim, JonesResearch Coverage and BPL-003 Control Might Change The Case For Investing In AtaiBeckley (ATAI) - simplywall.st
HC Wainwright remains bullish on AtaiBeckley Inc. (ATAI) - MSN
AtaiBeckley Inc. (ATAI) Stock Analysis: A 219.60% Upside Potential In Innovative Mental Health Treatments - DirectorsTalk Interviews
7 Best Fast Growing Penny Stocks to Buy According to Analysts - Insider Monkey
Guggenheim Initiates Buy Rating for AtaiBeckley (ATAI) With $11 PT, Cites Leadership in Psychiatry - Insider Monkey
H.C. Wainwright Remains Bullish on AtaiBeckley Inc. (ATAI) - Insider Monkey
Ataibeckley completes redomiciliation to the US - MSN
AtaiBeckley Inc. (ATAI) Stock Analysis: A Biotech Gem With Over 200% Upside Potential - DirectorsTalk Interviews
Psychedelic: Analyst initiates Atai Beckley with Buy rating - TipRanks
Assessing AtaiBeckley (ATAI) Valuation After Recent Share Price Pullback - simplywall.st
Small cap wrap: American Resources, C3 Metals, TNR Gold, AtaiBeckley... - Proactive Investors
Assessing AtaiBeckley (ATAI) Valuation After Trial Success Index Addition Capital Raise And US Move - Yahoo Finance
AtaiBeckley seen as key beneficiary of Spravato’s strong growth: Jefferies - Proactive financial news
AtaiBeckley Weighs Late Stage Options After Milestones And US$300m Raise - simplywall.st
The Bull Case For AtaiBeckley (ATAI) Could Change Following Promising BPL-003 Phase 2b Depression Data - Yahoo Finance
Guggenheim Initiates AtaiBeckley at Buy With $11 Price Target - marketscreener.com
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 - Finviz
Atai Beckley N.V. (ATAI) Achieves Significant Milestone on Pipeline Development and Corporate Foundation - Finviz
Assessing AtaiBeckley (ATAI) After A 149% Year Following Biotech Sector Sentiment Shift - simplywall.st
Small cap wrap: Nextech3D.ai, Aftermath Silver, Tiziana Life Sciences, AtaiBeckley… - Proactive financial news
Is AtaiBeckley (ATAI) Turning Psychedelic Trial Momentum Into a Durable Mental Health Moat? - simplywall.st
Interesting ATAI Call Options For March 20th - Nasdaq
Atai Beckley announces presentations at ACNP - TipRanks
AtaiBeckley shares clinical and preclinical data at ACNP Annual Meeting - Proactive financial news
AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation - Investing News Network
AtaiBeckley Inc. Showcases Breakthrough Findings on BPL-003 for Treatment-Resistant Depression at ACNP Annual Meeting - Quiver Quantitative
Single-dose nasal spray shows rapid effect in hard-to-treat depression - Stock Titan
A Look At AtaiBeckley (ATAI) Valuation After Phase 2b Progress And Delaware Redomiciliation - simplywall.st
Atai Beckley N.V. (ATAI) is a Buy on Mental Therapeutics Opportunities - Finviz
10 Best Penny Stocks to Buy for 2026 - Insider Monkey
AtaiBeckley Completes Redomiciliation to the United States - Investing News Network
New Strong Sell Stocks for Jan. 13 - The Globe and Mail
atai Life Sciences stock rating reiterated by Cantor Fitzgerald - Investing.com
AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio - Investing News Network
AtaiBeckley Added to the Nasdaq Biotechnology Index - Investing News Network
Is It Too Late To Reassess AtaiBeckley (ATAI) After A 150% One Year Rally? - simplywall.st
Is It Too Late To Consider AtaiBeckley (ATAI) After A 145% One-Year Surge? - Yahoo Finance
Atai Beckley CEO says entering 2026 with ‘meaningful momentum’ - The Globe and Mail
AtaiBeckley outlines 2026 mental health treatment pipeline milestones By Investing.com - Investing.com Nigeria
Ataibeckley Inc Stock (ATAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):